Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

Conditions:   Chronic Kidney Diseases;   Acute Coronary Syndrome
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   North Texas Veterans Healthcare System
Recruiting - verified May 2017

Optical Coherence Tomography in Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   STEMI - ST Elevation Myocardial Infarction;   NSTEMI - Non-ST Segment Elevation MI;   Atherosclerosis, Coronary
Sponsors:   Charite University, Berlin, Germany;   Berlin Institut of Health (BIH), Germany
Recruiting - verified May 2017

Coronary Anatomy Study and Times Since the Onset of Acute Myocardial Infarction Symptoms in Women Until the Opening of the Artery (TAPAC Study)

Condition:   Myocardial Infarction
Intervention:   Other: Non intervention
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Not yet recruiting - verified April 2017

A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered

Condition:   Sickle Cell Disease
Interventions:   Drug: Ticagrelor granule;   Drug: Ticagrelor pediatric tablets;   Drug: Ticagrelor pediatric tablets suspended in water;   Drug: Ticagrelor immediate release (IR) tablets (Commercial tablet)
Sponsors:   AstraZeneca;   Parexel
Recruiting - verified May 2017

Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes

Condition:   Ischemic Heart Disease
Interventions:   Drug: Proleukin;   Drug: Placebo Injection
Sponsors:   Cambridge University Hospitals NHS Foundation Trust;   University of Cambridge
Not yet recruiting - verified May 2017

Manipal Heart Failure Registry (MHFR)

Conditions:   Heart Failure;   Systolic Heart Failure;   Diastolic Heart Failure;   Decompensated Heart Failure;   Acute Heart Failure
Sponsor:   Manipal University
Recruiting - verified May 2017

PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure

Conditions:   Heart Failure;   Acute Heart Failure
Interventions:   Device: CHIARA-System;   Other: Usual care IV diuretics
Sponsor:   Fresenius Medical Care Deutschland GmbH
Not yet recruiting - verified May 2017

Outcomes in UK ACS Patients Prescribed Ticagrelor

Condition:   Acute Coronary Syndrome
Sponsor:   AstraZeneca
Completed - verified May 2017

The PROtective Ventilation Using Open Lung Approach Or Not Trial

Conditions:   Postoperative Pulmonary Complications;   Respiratory Insufficiency
Intervention:   Procedure: open lung approach
Sponsor:   Sixth Affiliated Hospital, Sun Yat-sen University
Recruiting - verified May 2017

Physical Activity Intervention for Patients With Reduced Physical Performance After Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Other: physical activity intervention;   Other: standard of care
Sponsor:   University Hospital of Ferrara
Recruiting - verified May 2017

Intraoperative Use of Extracorporeal Cytokine Adsorption During Orthotopic Heart Transplantation

Conditions:   Cardiac Transplantation;   Cardiopulmonary Bypass
Intervention:   Device: CytoSorb®
Sponsor:   Semmelweis University
Not yet recruiting - verified May 2017

Evaluation of Coronary Artery Plaque Volume Progression/Regression and Safety of Alirocumab in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

Conditions:   Hypercholesterolemia;   Acute Coronary Syndrome
Interventions:   Drug: alirocumab SAR236553;   Drug: atorvastatin;   Drug: rosuvastatin;   Drug: fenofibrate;   Drug: bezafibrate;   Drug: ezetimibe;   Drug: antiplatelets;   Drug: anticoagulants
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified May 2017

ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial

Conditions:   Coronary Disease;   Myocardial Infarction
Interventions:   Drug: Tocilizumab;   Drug: Sodium chloride 0.9%
Sponsors:   Oslo University Hospital;   St. Olavs Hospital;   South-Eastern Norway Regional Health Authority;   University of Oslo;   Norwegian University of Science and Technology
Recruiting - verified May 2017

Vitamin D to Improve Outcomes by Leveraging Early Treatment

Conditions:   Acute Respiratory Distress Syndrome;   Vitamin D Deficiency;   Critical Illness
Interventions:   Drug: Vitamin D3;   Drug: Placebo
Sponsors:   Massachusetts General Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2017

Effect and Efficacy of Onyx™, Zotarolimus-eluting Stent for Coronary Atherosclerosis

Conditions:   Coronary Artery Disease;   Acute Coronary Syndrome;   Myocardial Infarction;   Angina Pectoris
Intervention:   Device: Resolute Onyx
Sponsors:   Seoul National University Hospital;   Medtronic
Recruiting - verified May 2017

L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

Condition:   Acute Lung Injury
Interventions:   Drug: L-citrulline;   Other: Placebo
Sponsor:   Asklepion Pharmaceuticals, LLC
Recruiting - verified September 2016

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Conditions:   B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified May 2017

The Evaluation and Management of Patients With Acute Chest Pain in China

Conditions:   Acute Chest Pain;   Acute Coronary Syndrome
Sponsors:   Yuguo Chen;   People's Hospital of Jinxiang County;   People's Hospital of Chengwu;   Traditional Chinese Medicine Hospital of Wucheng County;   People's Hospital of Longkou City;   People's Hospital of Gaomi City;   Linyi People's Hospital;   People's Hospital of Wenshang County;   The 2nd People's Hospital of Liaocheng City;   People's Hospital of Shouguang City;   Traditional Chinese Medicine Hospital of Pingyin County;   Traditional Chinese Medicine Hospital of Laoling City;   The 2nd People's Hospital of Dongying City;   Affiliated Hospital of Shandong Academy of Medical Sciences;   People's Hospital of Shizhong District, Jinan City;   The 2nd People's Hospital of Dezhou City;   Central Hospital of Zibo City;   Jining Medical University;   People's Hospital of Mudan, Heze City;   The 3rd People's Hospital of Jinan City;   Qianfoshan Hospital;   Xinlongzhuang Colliery Hospital;   The 2nd Traditional Chinese Medicine Hospital of Taian City;   Qilu Hospital of Shandong University
Recruiting - verified May 2017

ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts

Conditions:   Coronary Artery Disease;   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Aspirin 100 mg;   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   University Hospital of Ferrara
Completed - verified May 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified May 2017

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

Conditions:   Neurofibroma, Plexiform;   Precursor Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Prolymphocytic, Acute;   Sarcoma
Intervention:   Drug: PLX3397
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified March 3, 2017

Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension

Condition:   Acute Coronary Syndromes
Sponsor:   AstraZeneca
Completed - verified May 2017

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Sponsor:   AstraZeneca
Active, not recruiting - verified May 2017

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 9, 2016

Prognosis of Anxiety in Intensive Care Unit

Condition:   Anxiety
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified October 2016

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified May 2017

Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide

Condition:   Chronic Granulomatous Disease
Interventions:   Drug: Pre-Transplant Conditioning Medications;   Other: Haploidentical Cellular Infusion;   Drug: Post-Trasnplant Medications;   Radiation: Total Body Irradiation
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Suspended - verified April 7, 2017

Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS

Condition:   Respiratory Distress Syndrome, Adult
Interventions:   Device: Prismalung;   Other: Ultra-protective ventilation;   Other: Conventional Lung Protective Ventilation
Sponsors:   National University Health System, Singapore;   Baxter Healthcare Corporation
Not yet recruiting - verified May 2017

Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

Condition:   Sickle Cell Disease
Intervention:   Drug: Hydroxyurea
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Enrolling by invitation - verified January 31, 2017

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Conditions:   Chronic Lymphocytic Leukemia;   CML (Chronic Myelogenous Leukemia);   MDS (Myelodysplastic Syndrome);   Acute Lymphoblastic Leukemia;   AML (Acute Myelogenous Leukemia)
Interventions:   Biological: MVST;   Biological: MVSTr
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 16, 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified May 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified May 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified May 2017

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

Condition:   Atherosclerosis
Interventions:   Drug: Darapladib;   Drug: Diltiazem
Sponsor:   GlaxoSmithKline
Completed - verified May 2017

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

Conditions:   MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention:   Device: Graft Manipulation (CD34+ Selection)
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Children's Research Institute
Recruiting - verified April 6, 2017

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Conditions:   Myeldysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia;   Bone Marrow Diseases;   Neutropenia;   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Clofarabine;   Drug: Lenalidomide
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Celgene Corporation
Completed - verified February 13, 2017

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
Interventions:   Other: Antitumor Drug Screening Assay;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Other: Pharmacological Study;   Drug: Ponatinib Hydrochloride;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified May 2017

Transplants With Unlicensed Preserved Cord Blood

Conditions:   Myelodysplastic Syndrome (MDS);   Hematologic Neoplasms;   Hematologic Diseases;   Severe Aplastic Anemia
Intervention:   Procedure: Cord Blood Transplant
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 6, 2016

Improving Blood Stem Cell Collection and Transplant Procedures

Conditions:   Myelodysplastic Syndrome (MDS);   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   CML (Chronic Myelogenous Leukemia;   CLL (Chronic Lymphocytic Leukemia)
Intervention:   Procedure: Stem Cell Transplantation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified March 29, 2017

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

Conditions:   Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
Interventions:   Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2, 2017

A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)

Conditions:   Myelodysplastic Syndromes;   Thrombocytopenia
Intervention:   Drug: Eltrombopag
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 16, 2017

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Condition:   Non-Malignant
Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2017

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

Conditions:   Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions:   Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2, 2017

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Conditions:   Immunosuppression;   Leukemia
Intervention:   Device: SOLEX 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified November 21, 2016

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Conditions:   Lymphoma;   Leukemia;   Myeloproliferative Disorders;   Multiple Myleoma;   Myelodysplastic Syndrome
Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Procedure: PBSC transplantation;   Genetic: T cell DLI with sirolimus generated donor TH-2 cells;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim;   Genetic: T-Rapa cell DLI
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified February 3, 2017

IC14 Antibodies to Treat Individuals With Acute Lung Injury

Conditions:   Respiratory Distress Syndrome, Adult;   Lung Diseases
Intervention:   Drug: IC14
Sponsors:   University of Washington;   National Heart, Lung, and Blood Institute (NHLBI)
Terminated - verified December 2007

Experimental Bone Marrow Transplant Protocol

Conditions:   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Acute Myelocytic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorders
Intervention:   Device: Isolex 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified July 14, 2016

Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy

Conditions:   Membranous Glomerulonephritis;   Lupus Membranous Nepropathy
Intervention:   Drug: Sirolimus
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified July 7, 2015

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Conditions:   Mycosis Fungoides;   Sezary Syndrome
Intervention:   Drug: Campath-1H
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified March 31, 2017

Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies

Conditions:   Hodgkin Lymphoma;   Lymphocytic Leukemia;   Mixed Cell Leukemia;   Myelodysplastic Syndrome;   Non Hodgkin's Lymphoma;   CML;   ALL;   AML;   Lymphoma
Intervention:   Procedure: Stem cell transplantation
Sponsor:   National Cancer Institute (NCI)
Completed - verified May 7, 2015

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

Conditions:   Wilms' Tumor;   Sarcoma;   Adenaocortical Carcinoma;   Refractory Cancer;   Coldrhood Cancer
Intervention:   Drug: Tariquidar
Sponsor:   National Cancer Institute (NCI)
Completed - verified January 13, 2016

Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults

Conditions:   Chronic Lymphocytic Leukemia;   Graft vs Host Disease;   Leukemia;   Myelodysplastic Syndrome;   Myeloid Leukemia
Intervention:   Procedure: Blood cell transplantation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified December 28, 2016

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

Conditions:   Chronic Lymphocytic Leukemia;   Graft vs Host Disease;   Hematologic Neoplasm;   Multiple Myeloma;   Myelodysplastic Syndrome
Intervention:   Device: Isolex 300i plus MoAbs
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified July 8, 2016

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow

Conditions:   Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention:   Procedure: Stem cell transplantation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 10, 2016

Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia

Conditions:   Graft vs Host Disease;   Hematologic Neoplasm;   Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome
Intervention:   Procedure: Allogeneic Bone Marrow Transplant
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 18, 2016